Eli Lilly's new oral weight-loss medication, Foundayo (generic name orforglipron), has garnered nearly 1,400 prescriptions in its first week of availability. The drug, approved on April 1st by the U.S. Food and Drug Administration (FDA), represents a significant new entry into the burgeoning GLP-1 market for obesity treatment.
The FDA has requested additional safety data from Eli Lilly concerning Foundayo, specifically regarding potential liver injury. The agency also mandated post-marketing trials to investigate cardiovascular risks and delayed gastric emptying associated with the drug. This regulatory attention comes as the once-daily pill enters the market, directly competing with existing treatments.
Foundayo's approval was fast-tracked, designated as a "National Priority" by the FDA. This expedited review process is part of a new FDA program designed to speed up decisions on medications deemed critical. The drug targets a different GLP-1 receptor than Eli Lilly's injectable offerings, Mounjaro and Zepbound. It is indicated for adults with obesity or those who are overweight with weight-related medical conditions, used in conjunction with a reduced-calorie diet and increased physical activity.
Read More: AI Chatbots Give Bad Health Advice, Study Finds
The drug is available in six dosage strengths, with pricing varying based on insurance coverage. Out-of-pocket costs for the lowest dose are reported around $149 per month, potentially reaching $349 per month for higher dosages. Many patients are expected to start at the lowest dose to mitigate common side effects, which include nausea, constipation, diarrhea, and indigestion.
The introduction of Foundayo intensifies the competition in the weight-loss drug sector, particularly against Novo Nordisk's oral GLP-1, Wegovy. Wegovy has already seen substantial prescription numbers since its market entry earlier this year. Analysts suggest that oral GLP-1 options like Foundayo may appeal to patients seeking more accessible administration compared to injectables, potentially addressing issues like insurance coverage complexities and patient preference for daily pills.
Eli Lilly's move to offer an oral GLP-1 medication aligns with broader industry trends and patient desires for less invasive treatment options. The company has also submitted orforglipron for regulatory review in over 40 countries, indicating a global launch strategy. Beyond weight management, studies have shown orforglipron can lead to reductions in cardiovascular risk factors, including waist circumference, blood pressure, and cholesterol levels.
Read More: Brooklyn Beckham says 'rocket arugula' sparking online debate
The development and approval of Foundayo underscore a shift in weight-loss treatment paradigms, offering another non-injectable GLP-1 option for individuals seeking to manage their weight. The drug's efficacy in clinical trials showed varying degrees of weight loss depending on the dosage, with higher doses yielding more significant results over a 72-week period.
Foundayo's approval under the Commissioner's National Priority Voucher program highlights its potential public health impact, aiming to cut down drug approval times for critical medications. This program's expedited nature means the drug reached the market swiftly following its assessment.
While Foundayo offers a new avenue for treatment, ongoing monitoring by the FDA will be crucial in assessing its long-term safety profile and overall impact on patient health. The company's claims about Foundayo's ability to "level the playing field" for individuals struggling with obesity suggest a proactive stance in addressing accessibility and treatment adherence challenges.
Read More: Health Secretary Kennedy Talks Food, Avoids Vaccine Policy Questions
